The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
Abstract
Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis. In a pilot study (n = 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases and the c-Met ligand hepatocyte growth factor/scatter factor (HGF/SF) in primary breast cancers and their lymph node metastases using both conventional immunohistochemistry and confocal immunofluorescence. Neither c-Met and HGF/SF nor Her2/neu expression correlated with established prognostic factors such as age, lymph node involvement, estrogen receptor (ER), progesterone receptor (PR), tumor size, or grade. Both staining methods confirmed a significant correlation between c-Met overexpression and a high risk of disease progression. Furthermore, among tumors with c-Met overexpression, only 50% also overexpress Her2/neu, thus identifying a subset of patients with aggressive disease in addition to Her2/neu. Median disease-free survival in patients with c-Met overexpressing tumors was 8 months compared to 53 months when c-Met expression was low (p = 0.037; RR = 3.0). This significant impact of c-Met on tumor aggressiveness independent of Her2/neu was also confirmed by multivariate analysis. In conclusion, the role of c-Met expression as a prognostic variable and consequently as an interesting target for novel therapeutic approaches deserves further analysis in a larger cohort of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Self-citationVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Nakajima, M., Sawada, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., Sakaguchi, T., Hirao, T., & Nakano, H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9%3c1894::aid-cncr3%3e3.0.co;2-j · Cited by 494
Yamashita, J.-I., Ogawa, M., Yamashita, S., Nomura, K., Kuramoto, M., Saishoji, T., & Shin, S.-I. (1994) · PubMed · Cited by 298
Yamauchi, H., Stearns, V., & Hayes, D. F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2334 · Cited by 291
Kang, J. J., Dolled-Filhart, M. P., Ocal, I. T., Singh, B., Lin, C.-Y., Dickson, R. B., Rimm, D. L., & Camp, R. L. (2003) · PubMed · Cited by 237
Expression of c-met is a strong independent prognostic factor in breast carcinoma
Ghoussoub, R. A. D., Dillon, D. A., D'Aquila, T., Rimm, E. B., Fearon, E. R., & Rimm, D. L. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980415)82:8<1513::aid-cncr13>3.0.co;2-7 · Cited by 217
Cao, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., Wang, L.-M., & Vande Woude, G. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131200498 · Cited by 213
Self-citationNiemann, C., Brinkmann, V., Spitzer, E., Hartmann, G., Sachs, M., Naundorf, H., & Birchmeier, W. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.2.533 · Cited by 132
Cited by
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
An overview of the c-MET signaling pathway
Organ, S. L., & Tsao, M.-S. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422556 · Cited by 875
Gene expression profiling of breast cell lines identifies potential new basal markers
Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adélaïde, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J., Birnbaum, D., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209254 · Cited by 569
Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S., & Basha, R. (2019) · Cancer Medicine · doi:10.1002/cam4.2560 · Cited by 449
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., Tabruyn, S. P., You, W.-K., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 408
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
c-MET as a potential therapeutic target and biomarker in cancer
Sierra, J. R., & Tsao, M.-S. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422557 · Cited by 365
Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via α5-Integrin, which Is a Therapeutic Target
Sawada, K., Mitra, A. K., Radjabi, A. R., Bhaskar, V., Kistner, E. O., Tretiakova, M., Jagadeeswaran, S., Montag, A., Becker, A., Kenny, H. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5167 · Cited by 356
Self-citationQian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
Blumenschein, G. R., Mills, G. B., & Gonzalez-Angulo, A. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3774 · Cited by 273
Sawada, K., Radjabi, A. R., Shinomiya, N., Kistner, E., Kenny, H., Becker, A. R., Turkyilmaz, M. A., Salgia, R., Yamada, S. D., Vande Woude, G. F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1147 · Cited by 258
Self-citationMetabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
Lanning, N. J., Castle, J. P., Singh, S. J., Leon, A. N., Tovar, E. A., Sanghera, A., MacKeigan, J. P., Filipp, F. V., & Graveel, C. R. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0168-x · Cited by 175
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110
Lai, X., Zhang, Y., Li, M., Yu, S., Wang, S., Zhang, S., Niu, H., Chen, L., Lan, X., Zhang, J., et al. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23878 · Cited by 11
Metadata
- Authors
- Lengyel, E., Prechtel, D., Resau, J. H., Gauger, K., Welk, A., Lindemann, K., Salanti, G., Richter, T., Knudsen, B., Vande Woude, G. F., & Harbeck, N.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004
- Volume
- 113
- Issue
- 4
- Pages
- 678-682
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1979491122
- Cited by
- 273
- References
- 15
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.